With regards to multi‐modal treatment approaches, PI3K/AKT pathway inhibition by means of GDC‐0941 enhances the efficacy of Axitinib against c‐myc‐amplified medulloblastoma. The gene discussed is MYC; the disease is medulloblastoma.